JPMorgan Raises Eli Lilly (LLY) Price Target to $1,150, Maintains Overweight Rating

Core Insights - Eli Lilly and Company (NYSE: LLY) is recognized as one of the 15 Best Stocks to Buy for the Medium Term [1] - JPMorgan has raised its price target for Eli Lilly to $1,150 from $1,050, maintaining an Overweight rating, following positive discussions with management [2] - The company has achieved significant success with its weight loss drugs, particularly in the GLP-1 inhibitor category, amid rising obesity rates [3] Financial Performance - In Q3 2025, Eli Lilly's revenue increased by 54% to $17.60 billion, primarily due to volume growth from its drugs Mounjaro and Zepbound [4] - Reported EPS rose by $5.14 to $6.21, while non-GAAP EPS increased by $5.84 to $7.02 [4] - The company is advancing its pipeline, with positive results from four Phase 3 trials of orforglipron for type 2 diabetes and obesity, aiming for global regulatory approval by year-end [4] Company Overview - Eli Lilly is a pharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines for various medical needs, including diabetes, oncology, immunology, neurodegeneration, and pain [5]